Semaglutide Win in HFpEF With Obesity Regardless of LVEF

Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.

Related Keywords

Cleveland ,Ohio ,United States ,United Kingdom ,Dallas ,Texas ,Massachusetts ,California ,Boston ,American ,America ,Bristol Myers Squibb ,Greggc Fonarow ,Muthiah Vaduganathan ,Johnw Ostrominski ,Coll Cardiol ,Javed Butler ,John Mcmurray ,Baylor Scott ,Los Angeles ,Eli Lilly ,University Of Glasgow ,Boehringer Ingelheim ,Heart Failure Society Of America ,Astrazeneca ,Tricog Health ,Johnson ,Novo Nordisk ,White Research Institute ,University Of Mississippi ,Pfizer ,University Of California ,Novartis ,Medtronic ,Amgen ,Harvard Medical School ,Bayer Ag ,Journal Of The American College Cardiology ,Lexicon Pharmaceuticals ,Heart Failure Society ,Scientific Meeting ,American College ,Medical Center ,American Regent ,Applied Therapeutics ,Cardiac Dimension ,Element Science ,Impulse Dynamics ,Baxter Healthcare ,Roche Diagnostics ,Failure Society ,Presented October ,Heart Failure ,Cardiovascular Imaging ,Ardiac Imaging ,V Imaging ,Ejection Fraction Ef ,Eft Ventricular Ejection Fraction Lvef ,Obesity ,Bese ,Bariatric Surgery ,Obesity Surgery ,Weight Loss Surgery ,Urgery Weight Loss ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Weight Loss ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Weight Management ,Receptor ,